Common use

Gleevec (imatinib mesylate) is a groundbreaking targeted cancer therapy prescribed for several types of malignancies, including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in all phases (chronic, accelerated, and blast crisis), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and gastrointestinal stromal tumors (GIST). Imatinib belongs to the class of tyrosine kinase inhibitors (TKIs) and works by selectively blocking the activity of the BCR-ABL fusion protein, an abnormal tyrosine kinase that drives uncontrolled cancer cell proliferation in CML and Ph+ ALL. In GIST, imatinib targets the KIT (CD117) and PDGFRA receptor tyrosine kinases. By inhibiting these oncogenic proteins, Gleevec effectively slows or stops tumor growth and promotes cancer cell death (apoptosis), often achieving durable remissions. Buy Gleevec online at DutyPills for affordable imatinib cancer treatment with reliable, discreet delivery.

Dosage and direction

Gleevec tablets are taken orally, typically once or twice daily depending on the specific cancer type and disease phase, with a meal and a large glass of water to reduce gastrointestinal irritation. Swallow tablets whole; do not crush or chew them. For patients who have difficulty swallowing, tablets may be dissolved in water or apple juice as directed by the prescribing oncologist. Dosage varies significantly: CML chronic phase is typically treated with 400 mg daily, while advanced phases or GIST may require 400-800 mg daily. Your oncologist will individualize the dose based on your cancer type, disease stage, body surface area, tolerability, and response to treatment. Regular monitoring of complete blood counts, liver function tests, kidney function, and disease-specific markers is essential throughout therapy.

Precautions

Before starting Gleevec, inform your oncologist if you have liver disease or impaired hepatic function, kidney disease, heart failure or cardiac disease, low blood counts (anemia, neutropenia, thrombocytopenia), a history of severe infections, or thyroid disorders (in patients who have had a thyroidectomy). Gleevec can cause significant fluid retention, which may manifest as periorbital edema, pleural effusions, ascites, or rapid weight gain; monitor for signs of swelling, shortness of breath, or unusual weight changes. Avoid pregnancy while taking Gleevec, as imatinib is known to cause serious birth defects. Both men and women of reproductive potential should use effective contraception during treatment. Avoid grapefruit and grapefruit juice during treatment, as they can increase imatinib blood levels.

Contraindications

Do not use Gleevec if you are allergic to imatinib mesylate or any of its inactive components. It is contraindicated during pregnancy due to demonstrated teratogenicity and during breastfeeding, as imatinib and its active metabolite are excreted in breast milk. Patients should not start Gleevec without confirmation of the appropriate molecular or genetic target by their oncology team.

Possible side effect

Common side effects of Gleevec imatinib include nausea, vomiting, diarrhea, muscle cramps and musculoskeletal pain, fatigue, skin rash, periorbital edema (puffiness around the eyes), abdominal pain, and headache. These are often mild to moderate and may improve with continued therapy. More serious side effects may include severe hepatotoxicity (liver damage with elevated transaminases), myelosuppression (dangerously low white blood cell, red blood cell, or platelet counts), severe fluid retention (pleural effusion, pericardial effusion, pulmonary edema), congestive heart failure, gastrointestinal hemorrhage, severe skin reactions, or tumor lysis syndrome. Seek immediate medical attention if you experience jaundice, severe bleeding, persistent shortness of breath, high fever, or any other alarming symptoms.

Drug interaction

Gleevec is extensively metabolized by the CYP3A4 enzyme system and may interact with numerous medications. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) can increase imatinib levels, raising the risk of toxicity. CYP3A4 inducers (rifampin, phenytoin, carbamazepine, dexamethasone, St. John’s wort) can decrease imatinib levels, potentially reducing efficacy. Imatinib itself inhibits CYP3A4, CYP2D6, and CYP2C9, which can increase levels of warfarin, simvastatin, cyclosporine, and many other drugs. Always inform your oncologist about all medications, supplements, and herbal products you are taking.

Missed dose

If you miss a dose of Gleevec, take it as soon as you remember on the same day. If it is already almost time for the next scheduled dose, skip the missed dose and resume your normal schedule. Do not double the dose. Contact your oncologist if you frequently miss doses, as consistency is important for optimal treatment outcomes.

Overdose

An overdose of Gleevec may cause severe nausea, vomiting, dangerously low blood counts, liver toxicity, muscle pain, fluid retention, or cardiac complications. There is no specific antidote for imatinib overdose. Seek immediate emergency medical attention if an overdose is suspected. Treatment is supportive and may include gastric decontamination if recent ingestion occurred.

Storage

Store Gleevec at room temperature between 20 and 25 degrees Celsius, protected from moisture, heat, and direct light. Keep the tablets in their original container, tightly closed, and out of the reach of children. Handle with care, as imatinib is a cytotoxic agent. Do not use beyond the expiration date.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.